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Pulsed electromagnetic fields stimulation
prevents steroid-induced osteonecrosis in rats
Shuai Ding, Hao Peng*, Hong-Song Fang, Jian-Lin Zhou and Zhe Wang
Abstract
Background: Pulsed electromagnetic fields (PEMF) stimulation has been used successfully to treat nonunion
fractures and femoral head osteonecrosis, but relatively little is known about its effects on preventing steroid-
induced osteonecrosis. The purpose of the study was to investigate the effects of PEMF stimulation on the
prevention of steroid-induced osteonecrosis in rats and explore the underlying mechanisms.
Methods: Seventy-two male adult Wistar rats were divided into three groups and treated as follows. (1) PEMF
stimulation group (PEMF group, n = 24): intravenously injected with lipopolysaccharide (LPS, 10 μg/kg) on day 0
and intramuscularly injected with methylprednisolone acetate (MPSL, 20 mg/kg) on days 1, 2 and 3, then subjected
to PEMF stimulation 4 h per day for 1 to 8 weeks. (2) Methylprednisolone-treated group (MPSL group, n = 24):
injected the same dose of LPS and MPSL as the PEMF group but without exposure to PEMF. (3) Control group (PS
group, n = 24): injected 0.9% saline in the same mode at the same time points. The incidence of osteonecrosis,
serum lipid levels and the mRNA and protein expression of transforming growth factor b1 (TGF-b1) in the proximal
femur were measured 1, 2, 4 and 8 weeks after the last MPSL (or saline) injection.
Results: The incidence of osteonecrosis in the PEMF group (29%) was significantly lower than that observed in the
MPSL group (75%), while no osteonecrosis was observed in the PS group. The serum lipid levels were significantly
lower in the PEMF and PS groups than in the MPSL group. Compared with the MPSL and PS groups, the mRNA
expression of TGF-b1 increased, reaching a peak 1 week after PEMF treatment, and remained high for 4 weeks,
then declined at 8 weeks, whereas the protein expression of TGF-b1 increased, reaching a peak at 2 weeks after
PEMF treatment, and remained high for 8 weeks.
Conclusions: PEMF stimulation can prevent steroid-induced osteonecrosis in rats, and the underlying mechanisms
involve decreased serum lipid levels and increased expression of TGF-b1.
Background
Osteonecrosis of the femoral head is the end point of a
disease process that results in progressive collapse of the
femoral head followed by destruction of the hip joint. It
has been recognized as a side effect of the corticosteroid
used to treat diseases such as Acute Respiratory Syn-
drome (SARS), Acquired Immunodeficiency Syndrome
(AIDS) and Systemic Lupus Erythematosus (SLE) [1-3].
High-dose corticosteroid administration is considered to
be the most common risk factor for osteonecrosis [4,5].
With the progression of osteonecrosis, both bone and
cartilage tissue are deformed, which ultimately leads to
collapse of the load-bearing area of the femoral head.
Once osteonecrosis collapses the femoral head, most
patients require surgical treatment. Several surgical
treatments have been established to prevent collapse,
such as core decompression [6], osteotomy [7], vascular-
ized or nonvascularized bone grafting [8] and joint
arthroplasty [9]. Most of them have certain effects in
selected series, but the costs and complications of sur-
gery cannot be ignored. Therefore, preventing osteone-
crosis would be an ideal strategy for the treatment of
this disease, but there is no established prophylactic
measure.
It is well documented that pulsed electromagnetic
fields (PEMF) are useful for enhancing bone repair in
nonunion fractures and related bone-healing problems
[10]. In addition, it was used successfully for the treat-
ment of osteonecrosis of the femoral head, especially at
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the early stage [11,12], but relatively little is known
about its effects on preventing steroid-induced osteone-
crosis. Furthermore, the mechanisms of PEMF stimula-
tion for the prevention of steroid-induced osteonecrosis
remained unclear, and the optimal protocol for PEMF
should be explored [13]. Transforming growth factor b1
(TGF-b1), involved in bone remodeling, is a multifunc-
tional cytokine. It plays an important role in controlling
osteoblast proliferation and differentiation in vivo [14].
Some studies demonstrate that mechanical interruption
by lipid emboli in the nutrient vessels can lead to vascu-
lar occlusion, and hyperlipidemia has been linked to the
development of osteonecrosis [15,16]. We proposed that
PEMF may be beneficial in preventing steroid-induced
osteonecrosis of the femoral head, and the underlying
mechanisms involve decreased serum lipid levels and
increased the expression of TGF-b1. As a preventive
therapy, PEMF could be used in combination with corti-
costeroid for treatment of many clinical conditions, such
as AIDS and SLE, which require high-dose corticoster-
oid treatment.
In this study, we investigated the preventive effect of
PEMF on steroid-induced osteonecrosis by examining
the incidence of osteonecrosis of the femoral head as
well as the serum lipid levels and the mRNA and pro-
tein expression of TGF-b1.
Methods
Animals
Seventy-two male adult Wistar rats (obtained from the
experimental animal center of Wuhan University),
weighing 250-280 g, were used in this study. All rats
were housed individually in custom-designed Plexiglas
cages (55 × 35 × 26 cm) under standard laboratory con-
ditions (12/12-h light/dark cycle, 24-25°C, humidity 50-
55%) and allowed free access to food and water during
the study. All experiment protocols adhered to the
Guidelines for the Care and Use of Laboratory Animals
published by the U.S. National Institutes of Health (NIH
Publication, revised 1996) and approved by the ethics
committee for Animal Research, Wuhan University,
China.
Grouping and treatment
All rats were divided into three groups by randomized
block design according to weight. (1) PEMF stimulation
group (PEMF group, n = 24): intravenously injected
with 10 μg/kg lipopolysaccharide (LPS, Escherichia coli
0111:B4, Sigma-Aldrich, St. Louis, MO, USA) on day 0
and injected with 20 mg/kg methylprednisolone acetate
(MPSL, Pfizer Pharmaceutical, China) into the right glu-
teus medius muscle on days 1, 2 and 3 at a time interval
of 24 h [17], then subjected to PEMF stimulation 4 h
per day for 1 to 8 weeks from day 4 onward. (2)
Methylprednisolone-treated group (MPSL group, n =
24): injected with the same dose of LPS and MPSL as
the PEMF group, with no exposure to PEMF. (3) Con-
trol group (PS group, n = 24): injected with 0.9% saline
in the same mode at the same time points. Six rats in
each group were sacrificed, and the samples were col-
lected 1, 2, 4 and 8 weeks after the last MPSL (or saline)
injection. The rats were anesthetized using pentobarbital
sodium (50 mg/kg ip; Westang Biotechnology, Inc.,
Shanghai, China). Blood samples were collected from
the inferior vena cava with the animals in a fasting state.
Then, the rats were sacrificed with an overdose of pen-
tobarbital sodium (240 mg/kg ip) and bilateral femurs
were harvested.
PEMF Generators
The PEMF generators consisted of a signal generator
and a pair of 40-cm diameter Helmholtz coils, which
were designed and manufactured by the Department of
Physics, Wuhan University, China. The Helmholtz coils,
each of which contained 500 turns of enameled copper
wire with diameter of 0.8 mm, were wound on a non-
conducting spool. The coils, equal to the width of the
cage, were separately placed at a distance of 25 cm. The
coils were connected to a signal generator that delivered
repetitive, single, square-wave pulses with pulse duration
of 4.5 ms and frequency of 15 Hz. The waveform of the
PEMF is presented in Figure 1. The frequency of the
PEMF was 15 Hz [13]. During each pulse, the magnetic
field increased from 0 to 12 G in 4.5 ms and then
decreased back to 0 in 20 ms. The rats in the PEMF
group were exposed to active pulsed electromagnetic
fields 4 h each day. The other rats were housed in iden-
tical cages, but with no stimulation.
Histopathology
The proximal one-third of right femurs was fixed in 4%
paraformaldehyde- 0.1 M phosphate buffer (pH 7.4), fol-
lowed by decalcification with 10% ethylenediaminete-
traacetic acid (EDTA)- 0.1 M phosphate buffer (pH 7.4).
After decalcification, the tissues were dehydrated in
Figure 1 Waveform of the PEMF. The frequency of the PEMF was
15 Hz. During each pulse, the magnetic field increased from 0 to 12
G in 4.5 ms and then decreased back to 0 in 20 ms.
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graded ethanol, embedded in paraffin, cut into 5-μm
thick sections in the coronal plane, and processed for
routine hematoxylin and eosin staining for the evaluation
of osteonecrosis. All sections were assessed blindly by
two independent authors (SD, HP), and the diagnosis of
osteonecrosis was established based on the presence of
empty lacunae or pyknotic nuclei of osteocytes in the
bone trabeculae, accompanied by surrounding bone mar-
row cell necrosis [18]. If the diagnoses differed between
the two examiners, a consensus was reached by discuss-
ing the histologic findings without knowledge of the
group from which the sample was obtained. The rats
with at least one osteonecrotic lesion in the area exam-
ined were considered to have developed osteonecrosis.
Hematological examination
The serum was collected by centrifugation at 3000 rpm
for 10 min at 4°C then stored at -80°C until hematologi-
cal examination. The levels of triglyceride (TG), total
cholesterol (TC), low-density lipoprotein cholesterol
(LDL) and high-density lipoprotein cholesterol (HDL) in
serum samples were determined by automatic biochem-
ical analyzer (AU 1000, Olympus, Japan).
Polymerase chain reaction (PCR) analysis
The unfixed proximal one-third of left femurs was
quick-frozen in liquid nitrogen and stored at -80°C for
subsequent mRNA and protein extraction. Samples were
weighed, followed by pulverization with a mortar and
pestle under liquid nitrogen in an Rnase-free condition.
Total RNA was extracted using Trizol Reagent (Invitro-
gen, Carlsbad, CA, USA) according to the manufac-
turer’s instructions. The concentration of RNA was
quantified by measuring the absorbance at 260 nm
(A260). The purity of RNA was assessed by determining
the A260/A280 ratio. The integrity and size distribution
of RNA were confirmed by formaldehyde-agarose gel
electrophoresis and ethidium bromide staining. The
RevertAid First Strand cDNA Synthesis Kit (Fermentas
Life Sciences, EU) was used to synthesize complemen-
tary DNA (cDNA). TGF-b1 cDNA was amplified by
PCR using the primers 5’- GGCGGTGCTCGCTTT
GTA-3’ (forward) and 5’-GCGGGTGACTTCTTTGGC-
3’ (reverse) (amplification product size 106 bp) [Gen-
Bank: NM021578]. b-actin cDNA was amplified as an
internal control using the primers 5’-TGGTGGGTA
TGGGTCAGAAGG-3’ (forward) and 5’-ATGGCTGGG
GTGTTGAAGGTC-3’ (reverse) (amplification product
size 265 bp) [GenBank: NM031144]. The cycle para-
meters of the reaction system included an initial dena-
turation step of 94°C for 5 min; amplification consisted
of 94°C for 30 s, 60°C for 30 s and 72°C for 45 s, fol-
lowed by a final extension step of 72°C for 10 min.
Thirty cycles (b-actin) and thirty-five cycles (TGF-b1) of
amplification were performed. PCR amplification pro-
ducts were analyzed by 1.5% agarose gel electrophoresis,
stained with ethidium bromide and photographed by the
Geliance 200 Imaging System (PerkinElmer, USA). The
optical density of the bands was analyzed with Quantity
One software (Bio-Rad Laboratories, Hercules, CA).
Gene expression was reported as the optical density
ratios of TGF-b1 to b-actin.
Western blot analysis
Samples dissected from the proximal one-third of left
femurs were powdered in liquid nitrogen by hand milling,
followed by homogenization in ice-cold radioimmunopreci-
pitation (RIPA, Beyotime institute of Biotechnology, China)
buffer containing phenylmethylsulfonyl fluoride (PMSF,
Beyotime institute of Biotechnology, China) and a cocktail
of protease inhibitors (Complete, EDTA-free; Roche, Man-
nheim, Germany). After sonication, the samples were cen-
trifuged twice at 14000 rpm at 4°C for 10 min to remove
cell debris, nuclei and large particulates. The supernatant
containing the cytosolic protein fraction was then collected.
A quarter volume of 5 × loading buffer was added and
boiled at 95°C for 5 min then stored at -20°C until electro-
phoresis. Proteins were separated by 10% sodium dodecyl
sulfate polyacrylamide gel and transferred to polyvinylidene
difluoride membranes (Millipore Corporation, Bedford,
MA). After being blocked with 2% bovine serum albumin
(Roche, Mannheim, Germany), the membrane was incu-
bated at 4°C overnight with rabbit anti-TGF-b1 antibody
(1:500, Santa Cruz Biotechnology, Santa Cruz, CA) or rab-
bit anti-b-actin antibody (1:500, Santa Cruz Biotechnology,
Santa Cruz, CA) as primary antibodies, followed by expo-
sure to peroxidase-conjugated secondary antibodies
(1:2000, Jackson Laboratories, West Grove, PA, USA) at
25°C for 1 h. The proteins on the membrane were visua-
lized using an ECL plus detection kit (Amersham Pharma-
cia Biotech, Buchinghamshire, UK), exposed to Kodak X-
ray film, then photographed by the Geliance 200 Imaging
System. The optical density of the bands was analyzed with
Quantity One software. The expression of TGF-b1 was
then normalized against b-actin.
Statistics
All data are presented as the mean ± SD. Statistical ana-
lysis was performed using SPSS 13.0 software (SPSS
Inc., Chicago, IL, USA). One-way analysis of variance
(ANOVA) with Turkey’s post hoc test was used to
examine differences between groups. Statistical signifi-
cance was set at P <0.05.
Results
Incidence of osteonecrosis
All rats survived during the experimental period. Figure
2 shows the histopathological appearance of the
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proximal one-third of the femur in the three groups
after hematoxylin and eosin staining at week 8. The
incidence of osteonecrosis is shown in Table 1. The
incidence of osteonecrosis was 7/24 in the PEMF group
(29%) and 18/24 (75%) in the MPSL group, while no
osteonecrosis was observed in the PS group. The inci-
dence of osteonecrosis in the PEMF group was signifi-
cantly lower than that in the MPSL group (P <0.05).
Hematological examination
The levels of TG, TC and LDL/HDL were significantly
increased from baseline in the MPSL group (P <0.05)
from week 1 onward, and the values increased up to a
maximum at week 2, then decreased from week 4
onward. No detectable changes were found upon the
hematological examinations of the PEMF or PS group.
The lipid levels were significantly lower in the PEMF
and PS groups than in the MPSL group at all time
points (P <0.05) (Figure 3A-C).
mRNA expression of TGF-b1
The mRNA expression of TGF-b1 in the PEMF group
was significantly higher compared with corresponding
samples in the MPSL group at all time points (P <0.05),
and significantly higher than that in the PS group at 1, 2
and 4 weeks after PEMF stimulation treatment (P
<0.05). Compared with the PS group, the expression of
TGF-b1 in the MPSL group was markedly suppressed
(P <0.05) (Figure 4A-B).
Protein expression of TGF-b1
Figure 5 shows the protein expression of TGF-b1 in the
proximal femur. The protein expression of TGF-b1 was
markedly higher in the PEMF group than in the MPSL
and PS groups at all time points (P <0.05). In contrast,
the protein expression of TGF-b1 was significantly
lower in the MPSL group than in the other two groups
(P <0.05).
Discussion
PEMF stimulation has been used successfully to treat
nonunion fractures and osteonecrosis of the femoral
head, but relatively little is known about its effects on
preventing steroid-induced osteonecrosis. Furthermore,
the mechanisms and the optimal protocol for PEMF sti-
mulation for the prevention of steroid-induced osteone-
crosis remain unclear. We investigated the preventive
effect of PEMF on steroid-induced osteonecrosis in rats
and explored the underlying mechanisms.
In the present study, the steroid-induced osteonecrosis
model was established in rats by a single injection of
low-dose LPS combined with three subsequent injec-
tions of high-dose MPSL [17]. The histopathology of
Figure 2 Histological appearance of the proximal one-third of femur in the three groups at week 8. (A) PS group. (B) MPSL group. (C)
PEMF group. The arrows represent empty lacunae or pyknosis of osteocytes in the bone trabeculae, accompanied by surrounding bone marrow
cell necrosis. (hematoxylin and eosin stain, ×100).
Table 1 Incidence of osteonecrosis of the femur (%).
Groups 1 week 2 weeks 4 weeks 8 weeks Total
PEMF 33 17 33 33 29*
MPSL 50 67 100 83 75
PS 0 0 0 0 0
*P <0.05 versus MPSL group.
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osteonecrosis generated in this model was characterized
by empty lacunae or pyknotic nuclei of osteocytes
accompanied by surrounding bone marrow cell necrosis,
which was similar to osteonecrosis in steroid- treated
patients. However, there are some differences in the
osteonecrosis observed in rats as compared to humans.
For example, osteonecrosis often leads to femoral head
collapse in humans but not in rats, as the epiphyseal
line of the femur is permanent in adult rats but not in
adult humans. In addition, the metabolic rates are
higher in rats than in humans, so osteonecrosis can be
observed in rats within one week after steroid treatment
[19]. In the present study, the incidence of osteonecrosis
(in the MPSL group) was 75%, and no rats died during
the experimental period, indicating that this rat model is
safe and effective. Thus, this model is useful for steroid-
induced osteonecrosis studies.
Since Bassett et al. [20] first reported the therapeutic
effects of PEMF in bone healing in 1974, the treatment
was widely used in nonunion fractures and related bone
healing problems. Different parameters of PEMF, such
as frequency, intensity and stimulation time, were
manipulated in clinical and experimental studies. How-
ever, the optimal parameters of PEMF are not known.
Figure 3 Hematological examination of rats in the three
groups. (A) TG. (B) TC. (C) LDL/HDL. Data are presented as the
mean ± SD. #P <0.05 versus PS group, *P <0.05 versus MPSL group.
Figure 4 mRNA expression of TGF-b1 in proximal femur. (A)
mRNA expression levels of TGF-b1 were evaluated by PCR analysis.
M: PCR marker, from bottom to top, the size is 250 and 500 bp. (B)
Data are expressed as expression ratios normalized to b-actin gene
expression and presented as the mean ± SD. #P <0.05 versus PS
group, *P <0.05 versus MPSL group.
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In this study, the choice of PEMF parameters was based
on a report by Ishida et al. [13], in which they found
that PEMF could reduce the risk of steroid-induced
osteonecrosis. We used the same electromagnetic fre-
quency, changed the stimulation time from 10 h to 4 h
per day, and obtained a similar incidence of
osteonecrosis.
The incidence of osteonecrosis in the PEMF group
was markedly lower than in the corresponding samples
in the MPSL group at all time points. The total inci-
dence of osteonecrosis was 29% versus 75% in the two
groups, respectively. Several researchers have shown
that steroid-induced osteonecrosis can be prevented by
anticoagulants or lipid-lowering agents, with reductions
in osteonecrosis that range from 30% to 40% [21,22].
Our study showed similar prevention effects, and no rat
suffered tissue damage due to the PEMF treatment.
Therefore, PEMF stimulation is a safe and effective
treatment for preventing osteonecrosis. We also found
that the incidence of osteonecrosis in the MPSL group
displayed a progression, while that in the PEMF group
did not. In the MPSL group, the incidence of osteone-
crosis increased to a peak at 4 weeks after the last
MPSL injection and then declined at 8 weeks. It is inter-
esting that the serum lipid levels in the MPSL group
showed a similar trend, increasing to a peak at 2 weeks
after the last MPSL injection and declining at 4 weeks.
This finding might indicate that hyperlipidemia contri-
butes to the pathogenesis of osteonecrosis.
Steroid treatment could increase adipogenesis and
decrease type-I collagen and ostecocalcin mRNA expres-
sion [5]. In addition, lipid-lowering agents were used to
prevent osteonecrosis and revealed satisfactory results
[21,22]. The data indicated that hyperlipidemia may be
one of the pathological mechanisms of steroid-induced
osteonecrosis. Therefore, the prevention of hyperlipide-
mia might also prevent steroid-induced osteonecrosis.
We consider that PEMF could prevent osteonecrosis
because several studies have shown that it can decrease
serum lipid levels [12,23]. Ishida et al. [13] also found
that PEMF did not affect bone marrow fat cell size and
hypothesized that its preventative effect on steroid-
induced osteonecrosis occurs via a mechanism indepen-
dent of lipid metabolism. Therefore, in the present
study, we measured only serum markers of adipogenesis,
including TG, TC, LDL and HDL, in order to explain
the underlying mechanism of PEMF stimulation in pre-
venting steroid-induced osteonecrosis. Assays of TG, TC
and LDL/HDL in the MPSL group showed a significant
increase compared with the PEMF and PS groups at all
time points. In contrast, the serum lipid levels were
similar between the PEMF group and the PS group.
Thus, we speculated that PEMF stimulation may prevent
osteonecrosis by decreasing serum lipid levels. The
underlying mechanism of PEMF in the living organism
remains unclear. Some theories have been proposed:
that the electromagnetic fields have the potential to reg-
ulate flow through cation channels, changing the steady-
state concentrations of cellular cations and thus the
metabolic processes dependent on cation concentra-
tions. We therefore hypothesize that the biological
effects of PEMF on serum lipids were associated with
ion-channel gating on the cell membrane [24,25].
As shown in previous studies, TGF-b1 is involved in
many aspects of skeletal development and regulation,
such as fracture repair and bone regeneration, as it can
promote the proliferation and differentiation of osteo-
blasts [14]. The results of this study showed that the
mRNA and protein expression of TGF-b1 was sup-
pressed in the MPSL group but up-regulated in the
PEMF group. Our findings are consistent with previous
studies, which reported that the expression of TGF-b1
could be enhanced through use of an electromagnetic
field (EMF) [26]. Therefore, it is highly likely that the
positive effect of PEMF stimulation on the expression of
TGF-b1 in the proximal femur of steroid-treated rats
contributes to the prevention of steroid-induced
osteonecrosis.
Although the pathophysiology of osteonecrosis of the
femoral head has not been completely elucidated, high-
Figure 5 Protein expression of TGF-b1 in proximal femur. (A)
The protein expression levels of TGF-b1 were evaluated by western
blot analysis. (B) Data are expressed as expression ratios normalized
to b-actin protein expression and presented as the mean ± SD. #P
<0.05 versus PS group, *P <0.05 versus MPSL group.
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dose corticosteroid administration is considered as the
most common risk factor for osteonecrosis [4,5].
Dosages typically considered to be associated with the
disease are > 2 g of prednisone, or its equivalent, within
a period of two to three months. Lower dosages are not
typically related to osteonecrosis of the femoral head
[4]. As a preventive therapy, PEMF could be used in
combination with corticosteroid for treatment of many
clinical conditions, such as AIDS and SLE, which
require high-dose corticosteroid treatment. Daily treat-
ment of PEMF is both time consuming and demanding;
patients may find it preferable to perform the treatment
at night. During the treatment, the coils were installed
separately on the sides of the bed to generate an electro-
magnetic field on the gluteofemoral area.
One limitation of this study is that we measured only
serum markers of adipogenesis, including TG, TC, LDL
and HDL, but did not evaluate the direct effect of
PEMF stimulation on adipogenesis in steroid-treated
rats. The other is that X-ray images were not used for
the evaluation of osteonecrosis.
Conclusions
In summary, PEMF stimulation can prevent steroid-
induced osteonecrosis in rats, and the underlying
mechanisms involve decreased serum lipid levels and
increased expression of TGF-b1. Because PEMF stimula-
tion is effective, safe and noninvasive, it provides a use-
ful prophylaxis for steroid-induced osteonecrosis.
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